Skip to main content
Ashleigh Kimberlin and Mikayla Molnar achieve success with a gas-trapping apparatus for Ac-225 production. Credit: ORNL, U.S. Dept. of Energy

In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.

Oak Ridge National Laboratory entrance sign

Balendra Sutharshan, deputy associate laboratory director for operational systems at DOE’s Pacific Northwest National Laboratory, has joined ORNL as associate laboratory director for the Isotope Science and Engineering Directorate.

COHERENT collaborators were the first to observe coherent elastic neutrino–nucleus scattering. Their results, published in the journal Science, confirm a prediction of the Standard Model and establish constraints on alternative theoretical models. Image c

After more than a year of operation at the Department of Energy’s (DOE’s) Oak Ridge National Laboratory (ORNL), the COHERENT experiment, using the world’s smallest neutrino detector, has found a big fingerprint of the elusive, electrically neutral particles that interact only weakly with matter.

By producing 50 grams of plutonium-238, Oak Ridge National Laboratory researchers have demonstrated the nation’s ability to provide a valuable energy source for deep space missions.

With the production of 50 grams of plutonium-238, researchers at the Department of Energy’s Oak Ridge National Laboratory have restored a U.S. capability dormant for nearly 30 years and set the course to provide power for NASA and other missions.